Skip to main content
Disc Medicine, Inc. logo

Disc Medicine, Inc. — Investor Relations & Filings

Ticker · IRON ISIN · US36870G1058 US Manufacturing
Open in API
Filings indexed 690 across all filing types
Latest filing 2023-12-12 Regulatory Filings
Country US United States of America
Listing US IRON

About Disc Medicine, Inc.

https://www.discmedicine.com/

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapies for patients with serious hematologic diseases. The company's research focuses on fundamental pathways of red blood cell biology to address a range of disorders. Its pipeline includes bitopertin, an investigational therapy for erythropoietic protoporphyria (EPP) for which a New Drug Application has been submitted for accelerated approval. Other clinical-stage programs are evaluating treatments for myelofibrosis-associated anemia and other conditions involving ineffective erythropoiesis.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated December 11, 2023, by Disc Medicine, Inc. It reports on a press release about data presented at a medical conference and an updated corporate presentation. The document includes a description of clinical study data and announces a conference call and webcast. It does not contain full financial statements or detailed financial analysis. The document is primarily an announcement of events and presentations rather than a full financial report or earnings release. The presence of a press release and investor presentation as exhibits further supports that this is a regulatory announcement rather than a detailed report. Therefore, the document fits best into the Regulatory Filings (RNS) category, which is the fallback for miscellaneous SEC filings like Form 8-K that do not fit other categories.
2023-12-12 English
8-K
Regulatory Filings Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC by Disc Medicine, Inc. It reports on a press release about data presented at a medical conference and announces a conference call to discuss the data and operational plans. The document includes a summary of clinical trial data and forward-looking statements. There are no comprehensive financial statements or detailed financial analysis typical of Annual Reports (10-K) or Interim Reports (IR). It is not a transcript of a call but an announcement of a call and data release. The document is primarily a regulatory filing to disclose material events and updates to investors, consistent with the purpose of Form 8-K filings. Therefore, the appropriate classification is Regulatory Filings (RNS).
2023-12-11 English
4
Director's Dealing
2023-12-07 English
Regulatory Filings 2023
Regulatory Filings
2023-12-07 English
8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events or changes that shareholders should know about. The content describes an amendment to an Open Market Sale Agreement increasing the aggregate offering price of shares the company may issue and sell. It details financing activity related to share issuance and registration statements. There are no financial statements or comprehensive financial performance data presented, so it is not an Annual Report (10-K) or Interim Report (IR). The focus is on capital raising and financing updates. Therefore, the document fits the Capital/Financing Update (CAP) category.
2023-12-05 English
POS AM
Regulatory Filings Classification · 100% confidence The document is titled 'Post-Effective Amendment No. 1 to Form S-3 Registration Statement' filed with the SEC. It discusses deregistration of securities previously registered under a Form S-3 registration statement, indicating it is an amendment to a registration statement related to securities offerings. The content is regulatory in nature, related to securities registration and deregistration, and does not contain financial statements, earnings data, or management discussion. It is not a report like an Annual Report or Earnings Release, nor is it a presentation or voting result. It is a formal regulatory filing concerning securities registration status. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length (6490 characters) and content confirm it is not merely an announcement but a substantive regulatory filing.
2023-12-05 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.